
Billiontoone Inc (BLLN) Stock Forecast & Price Target
Billiontoone Inc (BLLN) Analyst Ratings
Bulls say
BillionToOne Inc has demonstrated impressive revenue growth, achieving a year-over-year increase of 117% in its first quarter as a public company, along with a positive net income of $1.5 million for the first time in its history. The company's gross margins improved significantly to 53.0% in 2024, reflecting effective scaling and operational efficiency. Additionally, strong performance in both prenatal testing and oncology, highlighted by a 102% increase in prenatal test revenue and a staggering 664% increase in oncology revenue, underscores the potential for continued growth and a projected revenue compound annual growth rate (CAGR) of over 25% in the reproductive health sector.
Bears say
BillionToOne Inc faces a challenging outlook due to potential weaknesses in its competitive position if it cannot adequately protect its proprietary technology, which may impact future revenue streams. Additionally, the company may experience decreased reimbursement under the Clinical Laboratory Fee Schedule (CLFS) as rates are implemented, further pressuring its financial performance. This is compounded by higher denial rates from payers regarding the efficacy of its tests, leading to slower-than-expected revenue growth from both its core prenatal testing business and its recently launched oncology tests.
This aggregate rating is based on analysts' research of Billiontoone Inc and is not a guaranteed prediction by Public.com or investment advice.
Billiontoone Inc (BLLN) Analyst Forecast & Price Prediction
Start investing in Billiontoone Inc (BLLN)
Order type
Buy in
Order amount
Est. shares
0 shares